Atorvastatin has cardiac safety at intensive cholesterol-reducing protocols for long term, yet its cancer-treatment doses with chemotherapy may cause cardiomyopathy even under Coenzyme-Q10 protection

Cell Biochemistry and Function

Volumn 25, Issue 4, 2007, Pages 463-472

  Caner, Metin ^a   Sonmez, Bingur ^b   Kurnaz, Ozlem ^c   Aldemir, Caner ^c   Salar, Seda ^c   Altug, Tuncay ^a   Bilir, Ayhan ^d   Altinoz, Meric A ^e,f  

^a ISTANBUL UNIVERSITY   (Turkey)

^b MEMORIAL HOSPITAL   (Turkey)

^c Medical Biology Graduates

^d ISTANBUL UNIVERSITY   (Turkey)

^e Institute of Health in Halic (Golden Horn) University   (Turkey)

^f HALIC UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL; FOLIC ACID; HEPATOCYTE NUCLEAR FACTOR 4; METHOTREXATE; METHYLNITROSOUREA; MEVALONIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; STATINE DERIVATIVE; UBIDECARENONE;

ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG MEGADOSE; DRUG SAFETY; ELECTRON MICROSCOPY; FEMALE; HEART DEATH; HEART MITOCHONDRION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; STROKE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARDIOMYOPATHIES; COENZYMES; FEMALE; HEPTANOIC ACIDS; HUMANS; METHYLNITROSOUREA; MICROSCOPY, ELECTRON, TRANSMISSION; MITOCHONDRIA, HEART; PYRROLES; RATS; RATS, WISTAR; UBIQUINONE;

ANIMALIA; RATTUS;

EID: 34447515372     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.1356     Document Type: Article

References (32)

1. Kastelein JJ. The future of lipid-lowering therapy: the big picture. Neth J Med 2003; 61: 35-39.
2. de Lorgeril M, Salen P, Bontemps L, Belichard P, Geyssant A, Itti R. Effects of lipid-lowering drugs on left ventricular function and exercise tolerance in dyslipidemic coronary patients. J Cardiovasc Pharmacol 1999; 33: 473-478.
3. Ichihara K, Satoh K, Yamamoto A, Hoshi K. Are all HMG-CoA reductase inhibitors protective against ischemic heart disease? Nippon Yakurigaku Zasshi 1999; 114: 142-149.
4. Maltese WA, Aprille JR. Relation of mevalonate synthesis to mitochondrial ubiquinone content and respiratory function in cultured neuroblastoma cells. J Biol Chem 1985; 260: 11524-11529.
5. Sanguino E, Roglans N, Alegret M, Sanchez RM, Vazquez-Carrera M, Laguna JC. Atorvastatin reverses age-related reduction in rat hepatic PPARalpha and HNF-4. Br J Pharmacol 2005; 145: 853-861.
6. Lee HC, Yin PH, Lu CY, Chi CW, Wei YH. Increase of mitochondria and mitochondrial DNA in response to oxidative stress in human cells. Biochem J 2000; 348: 425-432.
7. Druzhyna N, Smulson ME, LeDoux SP, Wilson GL. Poly(ADP-ribose) polymerase facilitates the repair of N-methylpurines in mitochondrial DNA. Diabetes 2000; 49: 1849-1855.
8. Eizirik DL, Sandler S, Ahnstrom G, Welsh M. Exposure of pancreatic islets to different alkylating agents decreases mitochondrial DNA content but only streptozotocin induces long-lasting functional impairment of B-cells. Biochem Pharmacol 1991; 42: 2275-2282.
9. Wilander E. An ultrastructural study of pancreatic islet cell destruction by n-nitrosomethylurea. Acta Pathol Microbiol Scand [A] 1975; 83: 213-221.
10. Maekawa A, Matsuoka C, Onodera H, Tanigawa H, Furuta K, Ogiu T, Mitsumori K, Hayashi Y. Organ-specific carcinogenicity of N-methyl-N-nitrosourea in F344 and ACI/N rats. J Cancer Res Clin Oncol 1985; 109: 178-182.
11. Ketkar M, Reznik G, Haas H, Hilfrich J, Mohr U. Tumors of the heart and stomach induced in European hamsters by intravenous administration of N-methyl-N-nitrosourea. J Natl Cancer Inst 1977; 58: 1695-1699.
12. Holzhausen HJ, Schreiber D. Electron microscopic investigations on early stages of experimental heart tumours in rats. Exp Pathol (Jena) 1977; 13: 20-31.
13. Silver MA, Langsjoen PH, Szabo S, Patil H, Zelinger A. Statin cardiomyopathy? A potential role for Co-Enzyme Q10 therapy for statin-induced changes in diastolic LV performance: description of a clinical protocol. Biofactors 2003; 18: 125-127.
14. Newton CJ, Ran G, Xie YX, Bilko D, Burgoyne CH, Adams I, Abidia A, McCollum PT, Atkin SL. Statin-induced apoptosis of vascular endothelial cells is blocked by dexamethasone. J Endocrinol 2002; 174: 7-16.
15. Kanj SS, Sharara Al, Shpall EJ, Jones RB, Peters WP. Myocardial ischemia associated with high-dose carmustine infusion. Cancer 1991; 68: 1910-1912.
16. Cazin B, Gorin NC, Laporte JP, Gallet B, Douay L, Lopez M, Najman A, Duhamel G. Cardiac complications after bone marrow transplantation. A report on a series of 63 consecutive transplantations. Cancer 1986; 57: 2061-2069.
17. Phillips GL, Fay JW, Herzig GP, Herzig RH, Weiner RS, Wolff SN, Lazarus HM, Karanes C, Ross WE, Kramer BS. Intensive 1,3-bis(2-chloroethyl)-1- nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer. A phase I-II study. Cancer 1983; 52: 1792-1802.
18. Rigobello MP, Folda A, Scutari G, Bindoli A. The modulation of thiol redox state affects the production and metabolism of hydrogen peroxide by heart mitochondria. Arch Biochem Biophys 2005; 441: 112-122.
19. Paraidathathu T, Combs AB, Kehrer JP. In vivo effects of 1,3-bis(2-chloroethyl)-1-nitrosourea and doxorubicin on the cardiac and hepatic glutathione systems. Toxicology 1985; 35: 113-124.
20. Rabkin SW. Lovastatin induces cell death in cardiomyocytes that is not reversible by coenzyme Q 10. Pharmacol Toxicol 2002; 90: 343-345.
21. Rabkin SW, Kong JY. Lovastatin-induced cardiac toxicity involves both oncotic and apoptotic cell death with the apoptotic component blunted by both caspase-2 and caspase-3 inhibitors. Toxicol Appl Pharmacol 2003; 193: 346-355.
22. Hrab RV, Hartman HA, Cox RH Jr. Prevention of fluvastatin-induced toxicity, mortality, and cardiac myopathy in pregnant rats by mevalonic acid supplementation. Teratology 1994; 50: 19-26.
23. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators.
24. Kornbrust DJ, MacDonald JS, Peter CP, Duchai DM, Stubbs RJ, Germershausen JI, Alberts AW. Toxicity of the HMG-coenzyme A reductase inhibitor, lovastatin, to rabbits. J Pharmacol Exp Ther 1989; 248: 498-505.
25. Pan HY, DeVault AR, Wang-Iverson D, Ivashkiv E, Swanson BN, Sugerman AA. Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin. J Clin Pharmacol 1990; 30: 1128-1135.
26. Tanaka K, Honda M, Takabatake T. Anti-apoptotic effect of atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardiac myocytes through protein kinase C activation. Clin Exp Pharmacol Physiol 2004; 31: 360-364.
27. Senthil V, Chen SN, Tsybouleva N, Haider T, Nagueh SF, Willerson JT, Roberts R, Marian AJ. Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circ Res 2005; 97: 285-292.
28. Larner J, Jane J, Laws E, Packer R, Myers C, Shaffrey M. A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme. Am J Clin Oncol 1998; 21: 579-583.
29. Gliemroth J, Zulewski H, Arnold H, Terzis AJ. Migration, proliferation, and invasion of human glioma cells following treatment with simvastatin. Neurosurg Rev 2003; 26: 117-124.
30. Soma MR, Baetta R, De Renzis MR, Mazzini G, Davegna C, Magrassi L, Butti G, Pezzotta S, Paoletti R, Fumagalli R. In vivo enhanced antitumor activity of carmustine [N,N′-bis(2-chloroethyl)-N-nitrosourea] by simvastatin. Cancer Res 1995; 55: 597-602.
31. Ceylan A, Karasu C, Aktan F, Guven C, Can B, Ozansoy G. Effects of simvastatin treatment on oxidant/antioxidant state and ultrastructure of diabetic rat myocardium. Gen Physiol Biophys 2003; 22: 535-547.
32. Feleszko W, Mlynarczuk I, Balkowiec-Iskra EZ, Czajka A, Switaj T, Stoklosa T, Giermasz A, Jakobisiak M. Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice. Clin Cancer Res 2000; 6: 2044-2052.